Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Cancer Type, Cancer Stage, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)
The Middle East & African ovarian cancer diagnostics and therapeutics market is expected to register a CAGR of 9.2% during the forecast period, 2018 to 2023. GCC is expected to dominate the market for ovarian cancer diagnostics and therapeutics due to the increasing incidence of ovarian cancer.
Increasing Incidence of Ovarian Cancer
Ovarian cancer is the sixth most common cancer among women. The annual mortality rate per 100,000 people from ovarian cancer in North Africa and Middle East has increased by 20.1% since 1990, an average of 0.9% a year. Thus, the increasing incidence of ovarian cancer is fueling the growth of the Middle East & African ovarian cancer diagnostics and therapeutics market.
Additionally, greater use of combination therapies for the treatment of ovarian cancer, increasing population of aged women, and increase in healthcare expenditure in developing countries are fueling the growth of the Middle East & African ovarian cancer diagnostics and therapeutics market.
Lack of Accurate Diagnosis of Ovarian Cancer
Accurate diagnosis for ovarian cancer is critical, as in most cases, the cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early stage 1 detection is 93%, and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis. Lack of early detection and accurate diagnosis is often because ovarian cancer symptoms are frequently overlooked, and easily confused with other conditions. In addition, patent expiry of key drugs is also restraining the growth of the Middle East & African ovarian cancer diagnostics and therapeutics market.
GCC to Dominate the Market
Ovarian cancer is the 11th most common type of cancer in the GCC states. Between January 1998 and December 2004, 1,180 ovarian cancer cases were reported from all GCC states, which is 2.0% of all cancers and 4.0% of cancers among females. Bahrain reported the highest incidence of ovarian cancer. The age-standardized rate (ASR) per 100,000 women was 7.4 for Bahrain, followed by Qatar (6.7), Kuwait (5.9), Oman (5.5), UAE (4.4), and KSA (2.3).
Key Developments in the Market